NCT01304277View on ClinicalTrials.gov

This Study is Designed to Evaluate PD/PK and Safety of Replagal Manufactured by Two Different Processes.

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

November 17, 2011

Primary Completion Date

December 28, 2012

Study Completion Date

December 28, 2012

Conditions
Fabry Disease
Interventions
BIOLOGICAL

agalsidase alfa

Trial Locations (5)

T6G 2H7

University of Alberta Hospital, Edmonton

B3H 1V8

Queen Elizabeth II Health Sciences Centre, Halifax

M5G 1X8

The Hospital for Sick Children, Toronto

M5V 2T3

INC Research, Toronto

H4J 1C5

Hopital du Sacre-Coeur de Montreal, Montreal

Sponsors

Lead Sponsor

Shire
All Listed Sponsors
lead

Shire

INDUSTRY

NCT01304277 - This Study is Designed to Evaluate PD/PK and Safety of Replagal Manufactured by Two Different Processes. | Biotech Hunter | Biotech Hunter